Deep integration of proven AI tools into Philips cardiovascular ultrasound systems to better diagnose more cardiac disease patients
Philips (NYSE: PHG) has unveiled its next-generation AI-enabled cardiovascular ultrasound platform, integrating advanced AI applications into its EPIQ CVx and Affiniti CVx ultrasound systems. These innovations, cleared by the FDA, include the industry's first automated tool for segmental wall motion scoring, enhancing the detection of coronary artery disease and cardio-oncology issues. Additionally, Philips introduces the first fully automated 3D quantification of mitral regurgitation volumes, aiding in consistent and efficient analysis for heart valve disease patients. These advancements aim to speed up cardiac ultrasound analysis, improve diagnostic accuracy, and reduce the burden on echocardiography labs. The new AI tools, co-developed with DiA Imaging Analysis and other technology partners including NVIDIA, promise to enhance clinical decision-making, reduce re-scans, and shorten recovery times. Philips will present these innovations at the ASE2024 annual meeting.
- FDA clearance for new AI-enabled cardiovascular applications.
- First automated tool for segmental wall motion scoring.
- Automated 3D quantification of mitral regurgitation volumes.
- Enhances diagnostic accuracy and decision-making.
- Reduces re-scans and shortens interventional procedures.
- Improves efficiency and productivity in echocardiography labs.
- AI applications trained on real-life clinical data sets.
- Compatible with EPIQ CVx and Affiniti CVx systems.
- Solutions from DiA Imaging Analysis and NVIDIA integrated.
- Some features have 510(k) pending and are not available for sale in the USA.
- Potential high costs associated with integrating new AI technologies.
- Risk of over-reliance on AI for clinical decision-making.
- Possible challenges in adoption and training for new AI tools.
Insights
The integration of AI into Philips' cardiovascular ultrasound systems marks a significant step in enhancing diagnostic capabilities. The FDA clearance of these new AI applications, particularly in automated segmental wall motion scoring and 3D quantification of mitral regurgitation, underscores their clinical relevance. These innovations can help streamline workflow, reduce human error and offer more objective assessments than traditional methods. Moreover, these tools address a critical need in the growing field of cardiovascular health, which is essential given the substantial global burden of heart disease. For retail investors, these advancements indicate Philips’ commitment to pioneering healthcare technology and could result in increased market share and revenue growth in the long term.
From a financial perspective, Philips' announcement holds promising implications. The FDA clearance for AI-driven applications can boost the company's revenue streams by attracting more healthcare providers to its advanced cardiovascular ultrasound systems. Additionally, integrating AI addresses the efficiency and productivity issues faced by medical staff, potentially leading to higher adoption rates. This positions Philips well in a competitive market, aligning with broader industry trends towards automation and AI in healthcare. Investors should note the potential for increased sales and improved profit margins as these innovations gain traction.
Philips’ collaboration with NVIDIA and the integration of AI applications into their ultrasound systems is a notable example of leveraging cutting-edge technology to enhance medical diagnostics. The use of machine learning for real-time image analysis represents a significant leap in healthcare technology, offering faster and more reliable interpretations. This not only augments the capabilities of clinicians but also demonstrates Philips' strategic direction towards incorporating AI and machine learning into its product portfolio. For investors, this technological advancement could signify Philips’ potential to stay ahead of the curve in medical innovation, positioning the company as a leader in AI-enabled medical devices.
June 4, 2024
- New FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds
- First fully automated 3D quantification of mitral regurgitation (MR) volumes* designed to provide reproducible, efficient analysis helps clinicians make better-informed decisions for patients with heart valve disease
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs. Integrated into the company’s EPIQ CVx and Affiniti CVx ultrasound systems, the new FDA 510(k) cleared AI applications significantly advance Philips’ cardiovascular imaging and diagnosis solutions, automating measurements and speeding workflows to increase productivity.
Heart failure is a rapidly growing health issue that affects an estimated 64 million people worldwide [1]. It's also associated with high mortality and poor quality of life, and is a substantial burden on healthcare systems globally [2]. As the most common and least invasive way to check the structure and function of the heart, cardiovascular ultrasound has played a key role in diagnosing cardiac disease earlier.
“As clinical cases get more complex and patient volumes increase, we read hundreds of echocardiography exams daily with thousands of data points,” said Roberto Lang, MD, Director of the Noninvasive Cardiac Imaging Lab, University of Chicago Medicine, USA. “With the integration of AI into echocardiography solutions, we can now automate some of the steps to support clinicians' decision-making, allowing them to detect, diagnose, and monitor various cardiac conditions with greater confidence and efficiency in seconds.”
Dr. Lang will join other clinicians to share the results of a new scientific abstract being presented at the American Society of Echocardiography (ASE2024) annual meeting (June 14 – 16, Portland, US), demonstrating how first-of-kind AI algorithms co-developed with Philips provide highly accurate detection of regional wall motion abnormalities (RWMA) on echocardiography. RWMAs can be an independent indicator of adverse cardiovascular events and death in patients with cardiovascular diseases like myocardial infarction (MI) and congenital heart disease. Automated machine learning-based assessment of RWMA has the potential to improve the efficiency of all readers. “An advantage of AI methods over conventional visual analysis is that it can be performed in seconds, providing rapid and accurate information to help augment expert reads by quickly highlighting areas of concern for RWMA, improving the ease and efficiency of interpretation,” Lang added.
“By harnessing the power of AI into our echocardiography solutions, we empower clinicians with enhanced diagnostic capabilities, to ultimately improve patient care and outcomes in the management of coronary and valvular disease, while enhancing overall efficiency in cardiac practice,” said David Handler, VP and Business Leader for Global Cardiovascular Ultrasound at Philips. “For patients, this means consistent image interpretation which can lead to fewer re-scans, shorter and more effective interventional procedures, and potentially faster recovery times.”
Integration of proven AI applications from Philips DiA Imaging Analysis
Trained on anonymized patient data sets from real-life clinical environments, the AI features integrated across Philips cardiovascular ultrasound systems help improve the quality and reproducibility of cardiac imaging and enhance operator and departmental efficiency. These include FDA-cleared and CE-marked software solutions from DiA Imaging Analysis, a Philips company. Together, these AI features automate how users interpret ultrasound images, so clinicians with varying levels of ultrasound experience can automatically analyze images with increased speed, efficiency, and accuracy in real time.
In addition to integrating these latest advanced AI features into the company’s cardiovascular ultrasound systems, Philips’ new mini ultrasound transducer X11 4t, introduced earlier this year, is fully compatible with the EPIQ CVx and Affiniti CVx systems. The innovative transducer allows interventional cardiologists to provide enhanced care to a wider range of patients, including pediatric patients as small as 5kg in weight.
Through breakthrough innovation and collaborations with technology leaders including NVIDIA**, Philips continues to rapidly integrate AI into its cardiovascular ultrasound portfolio to help improve efficiency and productivity and mitigate staff shortages while delivering high-quality cardiology care to an increasing number of patients. These third-party solutions complement Philips’ proprietary AI-enabled solutions, integrating AI to enhance diagnostic confidence and decision-making.
For more information, join Philips in Booth #441 at ASE2024 and visit Philips Cardiovascular Ultrasound for the latest AI-powered echocardiography applications.
*Clinical performance and safety have not been established for some features which have 510(k) pending. Not available for sale in the USA.
**NVIDIA MONAI for medical imaging AI and NVIDIA Holoscan for building software-defined medical devices.
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
For further information, please contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978 221 8919
E-mail : kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Using AI technology to enhance assessment of heart function through cardiac ultrasound image analysis
- Using AI technology for automated evaluation of heart function through segmental wall motion scoring
- Clinical image showing how integrating AI into cardiac ultrasound provides automated segmental wall motion scoring
- Clinical image showing cardiac ultrasound display for image analysis enhanced through integration of AI.
FAQ
What new AI applications has Philips introduced into its cardiovascular ultrasound systems?
How does the new AI-enabled cardiovascular ultrasound platform by Philips improve cardiac diagnosis?
When and where will Philips present its new AI innovations in cardiovascular ultrasound?
What are the benefits of Philips' automated 3D quantification of mitral regurgitation volumes?
What partnerships has Philips leveraged to enhance its AI-enabled cardiovascular ultrasound solutions?
Are all features of Philips' new AI-enabled ultrasound systems available for sale in the USA?
What is the impact of Philips' new AI tools on echocardiography lab workflows?
